Login to Your Account

Pfizer's $527M Angiosyn Bid Not A Challenge To Macugen

By Randall Osborne

Tuesday, January 25, 2005
Building upon its ophthalmology franchise, Pfizer Inc. entered an agreement with Angiosyn Inc. to buy the privately held start-up for an up-front payment and other compensation valued at up to $527 million, not counting royalties, which also are part of the deal. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription